BIVI.US Biovie Inc

Healthcare Biotechnology USA Stocks
1.17 USD
Close of Nov 13, 2026
0.8200 3.79
Market cap
USD 12.5M
P/E
-
P/B
1.95x
ROE
-343.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is BIVI.US undervalued?

Graham number

The Graham number of Biovie Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biovie Inc fundamental analysis

No fundamental analysis for Biovie Inc yet.

Biovie Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biovie Inc

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is …

Full company profile